These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17133759)

  • 1. Detecting microalbuminuria and taking action in the cardiometabolic syndrome and type 2 diabetes mellitus.
    Hayden MR; Kolb L; Chowdbury N; Karuparthi PR; Khanna R; Sowers JR
    Mo Med; 2006; 103(5):533-8. PubMed ID: 17133759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening, monitoring, and treatment of albuminuria: Public health perspectives.
    de Jong PE; Curhan GC
    J Am Soc Nephrol; 2006 Aug; 17(8):2120-6. PubMed ID: 16825331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diabetes, hypertension and microalbuminuria in primary care].
    Bramlage P; Wittchen HU; Pittrow D; Dikow R; Kirch W; Lehnert H; Ritz E
    Fortschr Med Orig; 2003 Feb; 121 Suppl 1():33-8. PubMed ID: 14732948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of measurement of urinary albumin excretion in diabetes mellitus.
    Stehouwer CD; Donker AJ
    Neth J Med; 1993 Jun; 42(5-6):175-86. PubMed ID: 8377876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection.
    Whaley-Connell A; Pavey BS; Chaudhary K; Saab G; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):27-35. PubMed ID: 19124393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of modulating the renin-angiotensin system in preventing renal complications of hypertension.
    Rayner B
    Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):469-80. PubMed ID: 17186680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal manifestations in the metabolic syndrome.
    Locatelli F; Pozzoni P; Del Vecchio L
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S81-5. PubMed ID: 16565254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of the Dipstick Micraltest II in the screening of microalbuminuria of diabetes mellitus type 2 and essential hypertension.
    Cortés-Sanabria L; Martínez-Ramírez HR; Hernández JL; Rojas-Campos E; Canales-Muñoz JL; Cueto-Manzano AM
    Rev Invest Clin; 2006; 58(3):190-7. PubMed ID: 16958293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between hyperinsulinemia, hypertension and progressive renal disease.
    El-Atat FA; Stas SN; McFarlane SI; Sowers JR
    J Am Soc Nephrol; 2004 Nov; 15(11):2816-27. PubMed ID: 15504934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of metabolic syndrome with microalbuminuria in non-hypertensive type 2 diabetic patients.
    Lee JE; Huh W; Son HJ; Kim YG; Kim DJ; Lee MK; Oh HY
    Nephron Clin Pract; 2007; 106(3):c98-103. PubMed ID: 17522477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP).
    Kalaitzidis R; Li S; Wang C; Chen SC; McCullough PA; Bakris GL
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S22-31. PubMed ID: 19285608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microalbuminuria and cardiovascular disease.
    Weir MR
    Clin J Am Soc Nephrol; 2007 May; 2(3):581-90. PubMed ID: 17699466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.
    Vlek AL; van der Graaf Y; Spiering W; Visseren FL;
    J Hum Hypertens; 2008 May; 22(5):358-65. PubMed ID: 18273039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus.
    Araki S; Haneda M; Koya D; Kashiwagi A; Uzu T; Kikkawa R
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S54-8. PubMed ID: 18947896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microalbuminuria among type-2 diabetes mellitus patients in Pokhara, Nepal.
    Sigdel M; Rajbhandari N; Basnet S; Nagila A; Basnet P; Tamrakar BK
    Nepal Med Coll J; 2008 Dec; 10(4):242-5. PubMed ID: 19558062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians - the Chennai Urban Rural Epidemiology Study (CURES-38).
    Mohan V; Sandeep S; Deepa M; Gokulakrishnan K; Datta M; Deepa R
    Diabetes Obes Metab; 2007 May; 9(3):337-43. PubMed ID: 17391160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength?
    de Jong PE; Gansevoort RT; Bakker SJ
    J Nephrol; 2007; 20(4):375-80. PubMed ID: 17879201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of impaired glucose metabolism in Hispanics with two or more risk factors for metabolic syndrome in the primary care setting.
    Neira CP; Hartig M; Cowan PA; Velasquez-Mieyer PA
    J Am Acad Nurse Pract; 2009 Mar; 21(3):173-8. PubMed ID: 19302694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.